Brinker Capital Inc. reduced its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 8.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,147 shares of the biopharmaceutical company’s stock after selling 3,684 shares during the period. Brinker Capital Inc.’s holdings in Nektar Therapeutics were worth $1,320,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Laurel Wealth Advisors LLC purchased a new position in shares of Nektar Therapeutics during the 4th quarter worth about $39,000. Sandy Spring Bank purchased a new position in shares of Nektar Therapeutics during the 4th quarter worth about $59,000. Financial Architects Inc increased its position in Nektar Therapeutics by 91.6% during the 4th quarter. Financial Architects Inc now owns 2,092 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 1,000 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $101,000. Finally, Belpointe Asset Management LLC acquired a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $123,000. Institutional investors and hedge funds own 93.35% of the company’s stock.

NKTR opened at $32.61 on Thursday. The company has a market cap of $6.08 billion, a P/E ratio of 8.63 and a beta of 3.09. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $109.09. The company has a debt-to-equity ratio of 0.14, a current ratio of 17.53 and a quick ratio of 17.39.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. During the same period in the prior year, the business earned ($0.21) earnings per share. On average, analysts expect that Nektar Therapeutics will post -3.01 earnings per share for the current year.

In other Nektar Therapeutics news, COO John Nicholson sold 63,000 shares of the stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $42.82, for a total value of $2,697,660.00. Following the completion of the sale, the chief operating officer now owns 237,477 shares of the company’s stock, valued at $10,168,765.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jillian B. Thomsen sold 1,808 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $42.39, for a total transaction of $76,641.12. The disclosure for this sale can be found here. Insiders sold 241,824 shares of company stock valued at $10,249,993 in the last ninety days. 4.31% of the stock is owned by corporate insiders.

A number of research firms recently issued reports on NKTR. ValuEngine downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. BMO Capital Markets began coverage on shares of Nektar Therapeutics in a research report on Friday, February 22nd. They set an “outperform” rating and a $75.00 target price for the company. Svb Leerink began coverage on shares of Nektar Therapeutics in a research report on Friday, March 15th. They set a “mkt perform” rating and a $38.00 target price for the company. TheStreet raised shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a research report on Thursday, February 28th. Finally, HC Wainwright reissued a “hold” rating and set a $47.00 target price on shares of Nektar Therapeutics in a research report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. Nektar Therapeutics currently has an average rating of “Buy” and a consensus price target of $73.92.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2019/03/21/nektar-therapeutics-nktr-stake-decreased-by-brinker-capital-inc.html.

Nektar Therapeutics Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.